EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes

Abstract

<i>EGFR</i>-mutant lung SCC has a worse prognosis than <i>EGFR</i>-mutant adenocarcinoma. Mutations in other genes, such as <i>CREBBP</i>, <i>ZNF217</i>, <i>GRM8</i>, or Wnt that had implications on PFS raise the possibility of understanding mechanisms of resistance to EGFR-TKI in lung SCC, which will aid identification of potential beneficial subgroups of patients with <i>EGFR</i>-mutant SCCs receiving EGFR-TKIs.